Ray Dalio's REGN Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 235,381 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $132.35 M, representing 0.52% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Ray Dalio has maintained a long-term strategic position in REGN, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 146,334 shares. Largest reduction occurred in Q2 2024, reducing 55,792 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Regeneron Pharmaceuticals (REGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Regeneron Pharmaceuticals (REGN) Trades by Ray Dalio
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +4,101 | Add 0.00% | 4,100 | $224.88 |
| Q3 2013 | -4,100 | Sold Out | 4,100 | $0.00 |
| Q2 2014 | +18,400 | New Buy | 18,400 | $282.45 |
| Q3 2014 | -16,800 | Reduce 91.30% | 1,600 | $360.62 |
| Q4 2014 | +10,200 | Add 637.50% | 11,800 | $410.25 |
| Q1 2015 | -11,800 | Sold Out | 11,800 | $0.00 |
| Q2 2015 | +800 | New Buy | 800 | $510.00 |
| Q3 2015 | +1,000 | Add 125.00% | 1,800 | $465.00 |
| Q4 2015 | -1,800 | Sold Out | 1,800 | $0.00 |
| Q1 2016 | +900 | New Buy | 900 | $360.00 |
| Q2 2016 | -900 | Sold Out | 900 | $0.00 |
| Q3 2017 | +25,700 | New Buy | 25,700 | $447.12 |
| Q4 2017 | -25,700 | Sold Out | 25,700 | $0.00 |
| Q1 2018 | +21,872 | New Buy | 21,872 | $344.37 |
| Q2 2018 | -10,373 | Reduce 47.43% | 11,499 | $344.99 |
| Q3 2018 | +1,273 | Add 11.07% | 12,772 | $404.01 |
| Q4 2018 | -7,930 | Reduce 62.09% | 4,842 | $373.40 |
| Q1 2019 | -4,842 | Sold Out | 4,842 | $0.00 |
| Q2 2019 | +2,375 | New Buy | 2,375 | $312.84 |
| Q3 2019 | +59,330 | Add 2498.11% | 61,705 | $277.40 |
| Q4 2019 | -61,705 | Sold Out | 61,705 | $0.00 |
| Q2 2021 | +12,685 | New Buy | 12,685 | $558.53 |
| Q3 2021 | -5,263 | Reduce 41.49% | 7,422 | $605.23 |
| Q4 2021 | +113 | Add 1.52% | 7,535 | $631.59 |
| Q1 2022 | -2,083 | Reduce 27.64% | 5,452 | $698.46 |
| Q2 2022 | +68,448 | Add 1255.47% | 73,900 | $591.14 |
| Q3 2022 | -16,423 | Reduce 22.22% | 57,477 | $688.87 |
| Q4 2022 | -18,596 | Reduce 32.35% | 38,881 | $721.49 |
| Q1 2023 | +26,017 | Add 66.91% | 64,898 | $821.67 |
| Q2 2023 | +36,035 | Add 55.53% | 100,933 | $718.54 |
| Q3 2023 | -40,184 | Reduce 39.81% | 60,749 | $822.96 |
| Q4 2023 | +49,383 | Add 81.29% | 110,132 | $878.29 |
| Q1 2024 | -48,986 | Reduce 44.48% | 61,146 | $962.49 |
| Q2 2024 | -55,792 | Reduce 91.24% | 5,354 | $1051.03 |
| Q3 2024 | -4,797 | Reduce 89.60% | 557 | $1051.24 |
| Q4 2024 | -268 | Reduce 48.11% | 289 | $712.33 |
| Q1 2025 | +20,702 | Add 7163.32% | 20,991 | $634.23 |
| Q2 2025 | +68,056 | Add 324.22% | 89,047 | $525.00 |
| Q3 2025 | +146,334 | Add 164.33% | 235,381 | $562.27 |
Ray Dalio's Regeneron Pharmaceuticals Investment FAQs
Ray Dalio first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q2 2013, acquiring 4,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Regeneron Pharmaceuticals, Inc. (REGN) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q3 2025, adding 235,381 shares worth $132.35 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 235,381 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $132.35 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 0.52% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 235,381 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.